تقرير أداء عضو مجلس الإدارة المستقل في يونان بايياو، هو مينغشينغ، لعام 2025 منشور

China Information Network data Yunnan Baiyao Group Co., Ltd. recently released the 2025 annual performance report of its independent director Hu Mingxing. The report shows that after the company completed the re-election of the 11th board of directors on November 10, 2025, Hu Mingxing was elected as an independent director. During his term up to the end of the year, he strictly complied with relevant laws and regulations and the company’s articles of association, and diligently fulfilled his duties. In 2025, the 11th board of directors held a total of 2 meetings, and Hu Mingxing attended all of them in person, with no absences or proxy attendance. He also cast affirmative votes on all proposals. In addition, he attended 1 shareholders’ meeting.

As a member of the board’s Strategy Committee, Nomination Committee, and the Remuneration and Performance Appraisal Committee, Hu Mingxing attended all meetings of each special committee, for a total of 5 meetings. He considered key proposals including the election of the chair of each committee, the appointment of senior management, and the 2026 investment and wealth management plan. Meanwhile, as a member of the independent director special meeting, he attended all 2 meetings and conducted independent reviews of matters such as recommending the meeting convener and the expected daily related-party transactions for 2026.

During the course of fulfilling his duties, Hu Mingxing deepened his understanding of the company’s operating situation by attending meetings on-site and conducting on-the-ground inspections of the toothpaste smart factory and pharmaceutical production lines, among others, and maintained close communication with the company’s management. He emphasized that when reviewing proposals and supervising the performance of senior executives, he took as his starting point safeguarding the legitimate rights and interests of the company and all shareholders, especially small and medium-sized shareholders. Through self-examination, Hu Mingxing confirmed that his appointment meets the requirements of independence, and no circumstances affecting independence were found.

The report concludes that during Hu Mingxing’s term in 2025, he performed his duties diligently and effectively fulfilled the responsibilities of an independent director. Looking ahead to 2026, he stated that he will continue to be diligent and conscientious, and will use his own professional experience in the fields of biological engineering and pharmaceutical innovation to provide constructive suggestions for the company’s governance and development.

أخبار ضخمة وتحليلات دقيقة، كل ذلك على تطبيق Sina Finance